AZP-3813 / PeptiDream, AstraZeneca - LARVOL DELTA

Enhanced Ability of the Small Peptide GH Receptor Antagonist, AZP-3813, to Decrease IGF1 When Combined with the Somatostatin Analog, Octreotide (ENDO 2024) - "Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO."

Acromegaly • Endocrine Cancer • Endocrine Disorders • Oncology • Pituitary Gland Carcinoma • IGF1

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-3813, a Novel Small Peptide Growth Hormone Receptor Antagonist, in Healthy Subjects (ENDO 2024) - "Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO."

Clinical • P1 data • PK/PD data • Acromegaly • Endocrine Disorders • Pituitary Gland Carcinoma • Rare Diseases • IGF1

A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-3813, a Novel Small Peptide Growth Hormone Receptor Antagonist, in Healthy Subjects (ENDO 2024) - "Abstracts presented at a news conference are embargoed until the date and time of the news conference. The Endocrine Society reserves the right to lift the embargo on specific abstracts that are selected for promotion prior to or during ENDO."

Clinical • P1 data • PK/PD data • Acromegaly • Endocrine Disorders • Pituitary Gland Carcinoma • Rare Diseases • IGF1

Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca (GlobeNewswire) - "Amolyt Pharma...announced it has entered into a definitive agreement for AstraZeneca to acquire Amolyt Pharma at a purchase price of $800 million upfront and a potential milestone payment of $250 million....Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05B, on a cash and debt free basis."

M&A • Acromegaly • Hypoparathyroidism